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Abstract
Background: Impetigo, scabies, and fungal skin infections disproportionately affect populations in resource-limited
settings. Evidence for standard treatment of skin infections predominantly stem from hospital-based studies in
high-income countries. The evidence for treatment in resource-limited settings is less clear, as studies in these
populations may lack randomisation and control groups for cultural, ethical or economic reasons. Likewise, a
synthesis of the evidence for public health control within endemic populations is also lacking. We propose a
systematic review of the evidence for the prevention, treatment and public health management of skin infections
in resource-limited settings, to inform the development of guidelines for the standardised and streamlined clinical
and public health management of skin infections in endemic populations.
Methods: The protocol has been designed in line with the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses Protocols statement. All trial designs and analytical observational study designs will be eligible for
inclusion. A systematic search of the peer-reviewed literature will include PubMed, Excertpa Medica and Global
Health. Grey literature databases will also be systematically searched, and clinical trials registries scanned for future
relevant studies. The primary outcome of interest will be the clinical cure or decrease in prevalence of impetigo,
scabies, crusted scabies, tinea capitis, tinea corporis or tinea unguium. Two independent reviewers will perform
eligibility assessment and data extraction using standardised electronic forms. Risk of bias assessment will be
undertaken by two independent reviewers according to the Cochrane Risk of Bias tool. Data will be tabulated and
narratively synthesised. We expect there will be insufficient data to conduct meta-analysis. The final body of
evidence will be reported against the Grades of Recommendation, Assessment, Development and Evaluation
grading system.
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Discussion: The evidence derived from the systematic review will be used to inform the development of
guidelines for the management of skin infections in resource-limited settings. The evidence derived will be
intended for use by clinicians, public health practitioners and policy makers in the treatment of skin infections and
the development of skin infection control programmes. The review will identify any gaps in the current evidence to
provide direction for future research.
Systematic review registration: PROSPERO CRD42015029453
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Introduction
The skin infections impetigo, scabies and tinea dispropor-
tionately affect the most vulnerable populations [1–4].
Children in low-income countries, tropical regions and
disadvantaged populations within high-income countries
are amongst the worst affected [5–7]. Impetigo and scabies
are correlated; people with scabies are at risk of secondary
bacterial infection with impetigo and areas with a high
prevalence of one condition often have a high prevalence of
the other [5, 8]. Tinea infections (superficial mycoses) are
also common in tropical and resource-limited settings and
occur more frequently in children than in adult populations
[9, 10]. Tinea may also be complicated by impetiginisation
[9]. Without treatment of impetigo or secondarily infected
dermatoses, serious and sometimes fatal complications can
occur, including sepsis, invasive infection and post-
streptococcal sequelae [4, 11–16].
Impetigo
Impetigo is characterised by golden exudate and crust,
typically caused by the bacteria Staphylococcus aureus, the
prevalent bacteria in temperate regions, or Streptococcus
pyogenes (group A beta haemolytic Streptococcus (GAS)),
the predominant organism in tropical contexts [6, 17].
Impetigo can occur on any part of the body where breaks
in skin integrity have occurred [18–20]. Infestation with the
scabies mite is a major contributing factor in resource-
limited settings and tropical regions [6, 12, 21]. The global
paediatric population suffering from impetigo at any one
time has been estimated at >162 million; but this affliction
is not uniformly distributed, with children in tropical
regions and resource-limited settings carrying the greatest
burden of disease [22].
The medical treatment of impetigo comprises either top-
ical or systemic antibiotics directed at the two common
pathogens [23–26]. Hand hygiene [27], topical disinfectants
[24, 25] and school exclusion measures [28, 29] may be
used as adjuncts for treatment and contribute to disease
control. Natural therapies and traditional medicines such as
tea tree oil [30] and cocky apple tree poultices or suspen-
sions [31] are used by some populations.
Koning et al. concluded that the topical antibiotics,
fusidin and mupirocin, were the most effective treatment
for mild to moderate impetigo [24, 25]. However, the
majority of studies included in the review were con-
ducted in high-income countries and hospital outpatient
settings [24, 25]. In contrast, in Australian Aboriginal
and Torres Strait Islander communities, the recom-
mended treatment for impetigo has been intramuscular
benzathine penicillin, based on non-randomised trials
conducted over 40 years ago [32, 33]. Although Koning
et al. did not limit the Cochrane systematic review by
population and setting [24, 25], few studies were
included that involved populations in resource-limited
settings, as studies conducted in these settings may have
been non-randomised and uncontrolled and thus did
not satisfy inclusion criteria. As such, it is questionable
whether the findings, namely the first-line use of topical
antibiotics, can be recommended for treatment of impe-
tigo in resource-limited settings, particularly as impetigo
is often severe in these settings [21]. With recent
evidence showing the efficacy of oral trimethoprim-
sulfamethoxazole [21], growing concern regarding
antimicrobial resistance to topical agents [34] and rising
rates of methicillin-resistant S. aureus (MRSA) [35], a
review of the evidence base for effective treatment of
impetigo in resource-limited settings is needed. In
addition, primordial prevention interventions for impe-
tigo targeting the social determinants of health, which
underlie the burden of skin infections across the world
[1–3, 36], require review.
Scabies
Scabies, due to infestation by the mite Sarcoptes scabiei
var. hominis [4], is a human only skin disease charac-
terised by intense itch and cutaneous eruption [37, 38].
Scratching due to scabies interrupts the usual skin
barrier [37], facilitating the entry of bacteria, causing
secondary bacterial infection and its subsequent seque-
lae [37, 38]. Scabies mites crawl, but do not fly or jump;
thus transmission occurs through skin-to-skin contact
and occasionally through fomite spread [39, 40] as the
mite survives for several days off the human host [40].
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The estimated global prevalence of scabies in 2010 was
over 100 million people [41]. A recent systematic review
reported the highest point prevalence of paediatric scabies
in the resource-limited settings of Panama (78 % of chil-
dren under age 2 years affected), Fiji (44 % of 5- to 9-year-
olds affected) and Australia, where one third of Aboriginal
children in remote communities are affected [42].
Clinical treatment of scabies is with topical or oral
anti-parasitic agents [38, 43]. Herbal therapies and trad-
itional medicines, including natural pyrethrins, tea tree
oil [44] and emu bush [45], may also be effective, as well
as culturally acceptable in certain settings. Additional
methods for the prevention of transmission of scabies
include barrier precautions, environmental decontamin-
ation measures [40] and multifaceted population-level
approaches in endemic communities involving commu-
nity education, community involvement and treatment
of cases and contacts [46].
In the original Cochrane Review in 2000, Walker and
Johnstone concluded that topical permethrin was super-
ior to all other treatments for scabies [43]. In the 2007
update, oral ivermectin was supported as an effective
treatment, although was not licensed for use in the treat-
ment of scabies in many countries, and topical permeth-
rin remained superior to oral ivermectin [38]. This
systematic review needs updating to take into account
the recently published mass drug administration (MDA)
experimental studies [16, 47].
Beyond specific clinical treatment, a Cochrane review of
measures to reduce the transmission of scabies was unable
to provide recommendations due to a lack of RCTs exam-
ining these [40]. A systematic review of population-level
approaches to scabies prevention and control is needed but
challenging, due to lack of randomisation or comparisons
of programmatic approaches to scabies management in
endemic communities [48]. However, effective programmes
have been delivered in Australian Aboriginal communities
[49, 50]. As described by Wong et al., a programme deliv-
ered in a large Aboriginal community in the Top End of
the Northern Territory involving extensive community
support, education, screening of school children, MDA of
permethrin and environmental health services led to a
significant reduction in scabies and pyoderma prevalence at
7 [50] and 15 months [49]. As scabies is endemic in areas
where overcrowding, social disruption and poverty exist
[51, 52], a synthesis of the best available evidence for
scabies control that determines treatment effectiveness,
prevention of re-infection and cross-infection within
families and communities in resource-limited settings is
required [37, 43, 53].
Crusted scabies
Whilst classical scabies infestations involve 5 to 15 scabies
mites [37, 39], people with crusted (or Norwegian) scabies
have hyperinfestation with thousands to millions of mites
and are highly infectious [37, 38]. There is a spectrum of
severity, from mild cases to severe hyperkeratotic derma-
tosis [37]. The crusted scabies burden in remote Aboriginal
communities of the Northern Territory in Australia has
been estimated at 2.4 per 1000 population (Personal com-
munication, S. Prince 2016). The global burden of crusted
scabies is yet to be described.
Management of crusted scabies frequently involves
hospitalisation of the affected individual to prevent
community spread, provide frequent topical and sys-
temic scabicides along with application of keratolytics to
manage hyperkeratosis [46, 54, 55]. Environmental
measures are recommended to decontaminate the envir-
onment, where the heavy infestation of scabies mites can
survive for several days in the absence of the human
host, including washing of clothing and bed linen [37].
In addition, household spraying or fogging with insecti-
cides has been recommended in some clinical guidelines
to prevent transmission via fomites [56, 57].
Individuals with crusted scabies are core transmitters
of scabies within households or communities [37, 47].
Thus, public health interventions that identify and treat
people with crusted scabies in communities where
scabies is endemic are likely to reduce the burden of
scabies [53, 58]. However, social stigma associated with
scabies, particularly crusted scabies, is significant and
must be approached with respect and sensitivity [37, 58].
Community-based identification and management of
individuals with crusted scabies within the privacy of
their homes has been effective in the Northern Territory
of Australia using a chronic disease model of care [58].
The high transmissibility of crusted scabies from an
index case [40, 47] has implications for scabies control
in communities where individuals with crusted scabies
reside [47, 58]; hence, a review of the evidence for effect-
ive and socially acceptable methods of crusted scabies
management and control is needed.
Tinea/ringworm
Tinea infections are classified according to the site of
the human body affected [9]. Tinea corporis of the body,
tinea capitis of the scalp and tinea unguium [onychomy-
cosis] of the nail are caused by infection with dermato-
phytes of the genera Epidermophyton, Microsporum and
Trichophyton [10, 59].
Between 10 and 20 % of the world’s population are
affected by fungal skin infections [10]. Estimates of the
disease burden have generally focussed on the preva-
lence of causative organisms, rather than the clinical
disease entities [60, 61]. However, the World Health
Organization (WHO) has estimated that 7–33 % of
children assessed in clinical surveys in developing coun-
tries are affected by tinea capitis [17], and a recent
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systematic review reported the global prevalence of
onychomycosis as 11 % [62].
Clinical treatment for tinea infection includes oral and
topical antifungals and adjunctive treatment, such as
selenium sulphide shampoo [7, 9, 59]. Laser therapy for
tinea unguium is emerging [63–65] but its applicability
in resource-limited settings remains unknown.
Tinea is highly communicable, even amongst asymp-
tomatic carriers [9] with community-wide implications
for control programmes [17]. Identification of infected
contacts is important to prevent recontamination and
dissemination [17]. Additional methods for tinea control
include washing and disinfection of clothing, towels,
combs and brushes; discouraging sharing of these items
amongst household members; and concurrent treatment
of family members [9, 17].
Rationale for a systematic review applicable to resource-
limited settings
People living in regions with endemic rates of scabies and
impetigo [5, 66, 67] are at substantial risk of infective
complications, post-streptococcal sequelae and physical
disability [68, 69]. A coordinated and evidence-based ap-
proach to treatment and population management is needed
[17]. All Cochrane systematic reviews for the treatment of
impetigo, scabies and tinea relate to participants in high-
income countries, hospital settings and people with higher
socioeconomic status [10, 24, 25, 38, 40]. As such, there is
no current evidence-based consensus on the management
of skin infections found in the peer-reviewed literature to
support clinical and public health decision making in
endemic settings. We aim to develop guidelines for the
prevention, treatment and community control of impetigo,
scabies and fungal infections in resource-limited settings, as
the predominant skin infections in these populations [1, 17],
drivers of high demand for health care [17, 28, 66] and
potential precursors to rare but serious illness [13, 17]. To
develop a robust guideline for common skin infections in
endemic populations, a peer-reviewed, systematic review of
the evidence base applicable to resource-limited settings is
required. Due to the overlap between the occurrence of im-
petigo, scabies and fungal infections [8, 9] and the need for
streamlined guidance on the management of these common
conditions in resource-limited settings [17], a broad system-
atic review encompassing multiple conditions will be con-
ducted. The objective of the review is to assess the
evidence for treatment and public health management of
impetigo, scabies, crusted scabies, tinea capitis, tinea
corporis and tinea unguium in endemic settings.
Methods
This protocol is in accordance with the Preferred Report-
ing items for Systematic Reviews and Meta-Analyses-
Protocol (PRISMA-P) statement (Additional file 1) [70].
The systematic review will be conducted using standard
systematic review methodology based on the Cochrane
handbook and reported in accordance with the PRISMA
statement [71, 72]. The review will be overseen by a steer-
ing group, comprised of experts in the field. The review is
registered with PROSPERO (International prospective
register of systematic reviews) at the National Institute for
Health Research and Centre for Reviews and Dissemin-
ation (CRD) at the University of York (registration number
CRD42015029453).
Eligibility criteria
Types of participants and setting
The review will consider studies that include participants
of any age, gender or country of origin within resource-
limited settings, tropical regions, remote Aboriginal and
Torres Strait Islander communities and resource-limited
populations in Organisation for Economic Co-operation
and Development (OECD) countries or low, low-middle
and middle income countries. The review will include
people who have been diagnosed with impetigo, scabies,
crusted scabies, tinea capitis, tinea corporis or tinea
unguium.
Intervention
The review will examine any clinical or public health in-
terventions that aim to reduce skin infections. Treatment
interventions may include either pharmaceutical or com-
plementary medicines, including traditional management
of skin infections in relevant to the setting. Public health
interventions may include communicable disease control,
primary health care delivery, environmental health, health
promotion, education or community-level interventions.
Comparator
Studies with any type of comparator will be included.
Outcomes and prioritisation
The primary outcomes will include cure (i.e. resolution)
or improvement in the condition. A decrease in preva-
lence will be a primary outcome for population-based
studies. Secondary outcomes to be extracted will include
the clearance of organism on microbiological testing,
relief of symptoms, recurrence rate, adherence to treat-
ment or management regimen, patient acceptability,
adverse effects or the proportion of contacts diagnosed
with the condition within 8 weeks of diagnosis of the
index case [40].
Study design
Any experimental study designs will be eligible for inclu-
sion, including RCTs, quasi-experimental, before and after
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studies and cross over trials. The review will also include
cohort and case-control analytical study designs.
Information sources
Online databases of the peer- reviewed literature including
PubMed, Excerpta Medica Database (EMBASE) and Global
Health will be searched. In addition, grey literature will be
accessed via the Australian Institute of Health and Welfare
(AIHW), Australian Indigenous HealthInfoNet, Informit,
OaIster databases and World Health Organization (WHO)
website. In addition, clinical trial registries ANZ Clinical
Trials Registry, ClinicalTrials.gov and WHO International
Clinical Trials Registry will be searched to identify any
relevant studies underway. The reference lists of all
included full-text articles will be handsearched for relevant
titles for inclusion.
Search strategy
The search strategy aims to identify all relevant treat-
ments and public health interventions applied within a
resource-limited context regardless of publication status
(published, unpublished, in press or in progress). The
search strategy will use a combination of keywords and
subject headings relating to the setting and outcomes of
interest. A sample search strategy for PubMed is
included (Additional file 2). Terms will be adapted
according to the unique search features of the respective
databases. The search will be restricted to studies
published since 1960 for feasibility. Any study published
in English will be considered for inclusion in the review.




Titles and abstracts will be retrieved and screened using
Endnote reference management software. Full-text screen-
ing and data extraction will be managed using the web--
based software platform Covidence (Veritas Health
Innovation, Melbourne, VIC, Australia).
Selection process
Two independent reviewers will screen titles, and then
abstracts, for suitability using the index terms. Following
this, the full text of potentially relevant reports will be
retrieved where available. Full-text reports will be
assessed by two independent reviewers for compliance
with eligibility criteria. Reviewers will be assigned to a
subset of papers after determining that they are not
either an author of the paper or involved in data collec-
tion for the study. Where possible, we will attempt to
correspond with primary authors via email when eligibil-
ity for inclusion is unclear. Any disagreements that arise
between the reviewers regarding the studies for final
inclusion will be resolved via a consensus decision of the
review steering group. Members of the review steering
group who have authored a paper will be excluded from
any consensus decisions in relation to a paper they have
authored.
Data collection process
Data will be extracted using standardised forms by two
independent reviewers. Any disagreements will be resolved
by consensus amongst reviewers or will be referred to the
review steering group.
Data items
Data to be extracted from included studies comprises
the following: author, journal, study year or where
missing year of publication, funding source, study aims,
setting, study design, participants, intervention type,
frequency, dose, duration, co-intervention, primary out-
comes, secondary outcomes and results (including effect
estimates). Details of programme evaluation will be
extracted if available.
Risk of bias assessment
An assessment of methodological quality by the two
independent reviewers performing data extraction on a
study will be based on The Cochrane Collaboration’s
tool for assessing risk of bias [72]. For RCTs, this will
comprise the following: random sequence generation; al-
location concealment; blinding of participants, personnel
and outcome assessors; incomplete outcome data;
reporting bias and other sources of bias that may have
affected the results. As recommended by Higgins and
Greene, non-RCT experimental and controlled studies
will also use the domains based on The Cochrane
Collaboration’s tool for assessing risk of bias [72]. The
“other sources of bias” domain will include an assess-
ment for confounding for non-RCTs. For observational
studies, random sequence generation and allocation
concealment will not be applicable, but other domains
of blinding, incomplete outcome data, selective outcome
reporting and other sources of bias will be assessed,
which will include an assessment of identified and other
potential confounders. Risk of bias assessments will sub-
sequently be rated as high, low or unclear in a “Risk of
bias” table. Any disagreements that arise will be resolved
via a consensus decision of the review steering group.
Data synthesis
We expect there to be insufficient data to conduct meta-
analyses. Quantitative findings will be presented in
narrative form including additional technical tables and
figures to aid in data interpretation where appropriate.
Where possible, opinion-based findings will be synthe-
sised and presented in a “Characteristics of included
May et al. Systematic Reviews  (2016) 5:162 Page 5 of 8
information” tables or text. Results for each condition
will be presented in turn.
A single, comprehensive set of synthesised quantitative
findings will be presented in a “Summary of Findings” table
for each condition from which to develop guidelines. The
quality of the evidence will be rated using the Grading of
Recommendations, Assessment, Development and Evalu-
ation (GRADE) grading system [73].
Meta-biases
Studies will be included only once (i.e. multiple reports
of data from the same study will be screened by author
names, setting, institution, type of intervention and date
and duration of the study) to reduce the risk of publica-
tion bias. We will assess for evidence of selective
outcome reporting when the outcomes are described in
the “Methods” section but not reported in the “Results”
section of the same study report.
Confidence in cumulative evidence
We will assess the underlying reasons for any discrepan-
cies in results between studies, taking into account study
design characteristics and risk of bias. The strength of
the overall body of evidence will be reported against the
Grading of Recommendations, Assessment, Develop-
ment and Evaluation (GRADE) grading system [73].
Discussion
This review will provide a synthesis of the existing
literature applicable to resource-limited settings, with
GRADE evidence gradings [73], to inform the develop-
ment of guidelines for the management of skin infec-
tions in endemic populations and particularly Australian
Aboriginal and Torres Strait Islander communities.
Recommendations for skin infection prevention, treat-
ment, public health management and programme evalu-
ation will be the focus of the guideline. A limitation of
the review is that the methodology (i.e. the inclusion of
non-randomised trials and observational studies across
multiple conditions) will likely preclude formulation of
overall effect estimates via meta-analysis due to the
expected high heterogeneity between studies. Any
evidence gaps that are exposed will highlight areas for
future research. A summarised version of the review will
be submitted for publication. The guidelines and sum-
mary systematic review paper will be made available on
the Internet for use by clinicians and public health
practitioners. In addition, policymakers and health orga-
nisations may choose to use the evidence base as a
resource for the development of local treatment proto-
cols and skin health programmes.
Additional files
Additional file 1: PRISMA-P (Preferred Reporting Items for Systematic
review and Meta-Analysis Protocols) 2015 checklist: recommended items
to address in a systematic review protocol. (DOC 86 kb)
Additional file 2: PubMed Search Strategy. (DOCX 26 kb)
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